IP Library Granted Patent US 12,023,359
Granted Patent B2
US 12,023,359 · App. 18/381,439 · Granted Jul 2, 2024

Phospholipid compositions for delivery of therapeutic compounds

Inventors: Thomas Repstad (Stamsund, NO); Finn Myhren (Stamsund, NO); Nils Hoem (Stamsund, NO)
Assignee: AKER BIOMARINE HUMAN INGREDIENTS AS
A61K35/612A61K9/107A61K31/202
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,023,359
App. No.
18/381,439
Granted
Jul 2, 2024
Kind
B2
Abstract

The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.

Claims (22)

1. A lipid formulation for use in therapy by enhancing absorption of ethyl esters in a subject in need thereof, comprising:

a) from 17% w/w to 75% w/w total phospholipids, wherein w/w is the weight of the phospholipids per the total weight of the formulation, and wherein the phospholipids comprise more than 80% w/w phosphatidylcholine and wherein molar content of omega-3 moieties in the phospholipids is more than 25%; and

b) from 16% w/w to 50% w/w of ethyl esters of docosahexaenoic acid and/or eicosapentaenoic acid;

wherein the lipid formulation forms an emulsion with a droplet size of from 150 to 600 nm in an artificial stomach fluid determined through dynamic light scattering.

2. The lipid formulation of claim 1 , wherein the lipid formulation forms a droplet size of from 150 to 500 nm in an artificial stomach fluid determined through dynamic light scattering.

3. The lipid formulation of claim 1 , wherein the lipid formulation forms a droplet size of from 150 to 400 nm in an artificial stomach fluid determined through dynamic light scattering.

4. The lipid formulation of claim 1 , wherein the lipid formulation forms a droplet size of from 150 to 300 nm in an artificial stomach fluid determined through dynamic light scattering.

5. The lipid formulation of claim 1 , wherein the lipid formulation forms a droplet size of from 150 to 250 nm in an artificial stomach fluid determined through dynamic light scattering.

6. The lipid formulation of claim 1 , wherein the lipid formulation forms a droplet size of from 150 to 200 nm in an artificial stomach fluid determined through dynamic light scattering.

7. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 20% to 60% w/w of the phospholipids from a marine source.

8. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 30% to 50% w/w of the phospholipids from a marine source.

9. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 35% to 45% w/w of the phospholipids from a marine source.

10. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 37% to 43% w/w of the phospholipids from a marine source.

11. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 38% to 42% w/w of the phospholipids from a marine source.

12. The lipid formulation of claim 1 , wherein the phospholipids are from a marine source.

13. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 20% to 50% w/w of the ethyl esters selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof.

14. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 25% to 35% w/w of the ethyl esters selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof.

15. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 27% to 33% w/w of the ethyl esters selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof.

16. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 28% to 32% w/w of the ethyl esters selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof.

17. The lipid formulation of claim 1 , wherein the lipid formulation comprises from 29% to 31% w/w of the ethyl esters selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid and combinations thereof.

18. A method of enhancing absorption of ethyl esters in a subject in need thereof, comprising:

administering the formulation of claim 1 to the subject so that absorption of the ethyl esters is enhanced.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: AKER BIOMARINE ANTARCTIC AS
To: AKER BIOMARINE HUMAN INGREDIENTS AS
Reel/Frame 066703/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2023
From: REPSTAD, THOMAS; MYHREN, FINN; HOEM, NILS
To: AKER BIOMARINE ANTARCTIC AS
Reel/Frame 065361/0479 →
Priority Claims (1)
NO 20221173 · Nov 1, 2022 · national
Continuity (1)
Related Publication 20240156876A1 · May 16, 2024